electroCore, Inc.
NCM: ECORLive Quote
About electroCore, Inc.
Healthcare
Medical Devices
electroCore, Inc., a bioelectronic technology medicine and general wellness company, provides non-invasive vagus nerve stimulation (nVNS) technology platform in the United States, the United Kingdom, and internationally. The company develops gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga 350, a personal use consumer electronics general wellness product and Truvaga Plus, an app-enabled general wellness product. It also offers non-invasive bioelectronic therapies for the treatment of chronic pain and wellness conditions. In addition, the company offers TAC-STIM for human performance and gammaCore Sapphire, a portable, reusable, rechargeable, and reloadable prescription medical device for various primary headache conditions. electroCore, Inc. was incorporated in 2005 and is headquartered in Rockaway, New Jersey.
📊 Fundamental Analysis
electroCore, Inc. demonstrates a profit margin of -43.6%, which is below the sector average, suggesting competitive pressure.
The company recently reported 31.2% revenue growth, which is well above average for the Healthcare sector.
Return on Equity (ROE) is -478.7%, which indicates that capital utilization is currently under pressure.
At a current price of $6.08, ECOR currently sits at the 43rd percentile of its 52-week range (Range: $4.16 - $8.64).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Revenue Growth
Excellent
🔴
Return on Equity
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$78.98M
Trailing P/E
--
Forward P/E
-11.05
Beta (5Y)
0.60
52W High
$8.64
52W Low
$4.16
Avg Volume
74K
Day High
Day Low
📡 Subscribe to ZcoreAI updates
Join the list to get access to:
- Z-Score signals at market open
- New app features and updates
- Exclusive promo for ZcoreAI App